BeyondSpring Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
BeyondSpring has been growing earnings at an average annual rate of 15.4%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 47.6% per year.
Anahtar bilgiler
15.4%
Kazanç büyüme oranı
25.2%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 17.0% |
| Gelir büyüme oranı | 47.6% |
| Özkaynak getirisi | n/a |
| Net Marj | -829.9% |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation
Jun 21
BeyondSpring, Beyond Salvage
Feb 03Circling Back On BeyondSpring
Nov 16Upcoming News For BeyondSpring's Plinabulin Tees Up Big Potential Returns
Sep 18BeyondSpring: Poor Trial Conduct And Lack Of Transparency Create Substantial Downside Risk
Sep 07BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space
Aug 01BeyondSpring EPS misses by $0.04
Jun 16BeyondSpring reports positive plinabulin combo data for prevention of chemotherapy-induced neutropenia
Jun 07FDA grants accelerated review to BeyondSpring's plinabulin combo application; shares up 8%
Jun 01BeyondSpring EPS misses by $0.17
Apr 30How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?
Dec 22
BeyondSpring: Would Be A Great Buy Except For The Perennial Need For Cash And Ensuing Dilution
Dec 15BeyondSpring slides 9% on public offering pricing at $10.0/share
Nov 19BeyondSpring under pressure on shares offering
Nov 17BeyondSpring's plinabulin combo meets primary endpoint in neutropenia trial
Nov 16Gelir ve Gider Dağılımı
BeyondSpring nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 2 | -16 | 9 | 10 |
| 31 Mar 24 | 2 | -18 | 10 | 12 |
| 31 Dec 23 | 2 | -21 | 10 | 15 |
| 30 Sep 23 | 2 | -24 | 10 | 18 |
| 30 Jun 23 | 2 | -28 | 11 | 21 |
| 31 Mar 23 | 1 | -30 | 12 | 23 |
| 31 Dec 22 | 1 | -33 | 13 | 26 |
| 30 Sep 22 | 1 | -35 | 15 | 26 |
| 30 Jun 22 | 1 | -46 | 23 | 28 |
| 31 Mar 22 | 1 | -56 | 28 | 33 |
| 31 Dec 21 | 1 | -64 | 31 | 37 |
| 30 Sep 21 | 1 | -72 | 36 | 40 |
| 30 Jun 21 | 1 | -68 | 33 | 40 |
| 31 Mar 21 | 1 | -62 | 26 | 39 |
| 31 Dec 20 | 0 | -61 | 23 | 42 |
| 30 Sep 20 | 0 | -57 | 15 | 46 |
| 30 Jun 20 | 0 | -52 | 11 | 45 |
| 31 Mar 20 | 0 | -47 | 10 | 39 |
| 31 Dec 19 | 0 | -38 | 9 | 31 |
| 30 Sep 19 | 0 | -38 | 9 | 31 |
| 30 Jun 19 | 0 | -44 | 8 | 38 |
| 31 Mar 19 | 0 | -49 | 7 | 44 |
| 31 Dec 18 | 0 | -55 | 6 | 52 |
| 30 Sep 18 | 0 | -56 | 5 | 54 |
| 30 Jun 18 | 0 | -57 | 7 | 55 |
| 31 Mar 18 | 0 | -58 | 9 | 56 |
| 31 Dec 17 | 0 | -92 | 9 | 89 |
| 30 Sep 17 | 0 | -80 | 8 | 77 |
| 30 Jun 17 | 0 | -67 | 5 | 65 |
| 31 Mar 17 | 0 | -58 | 3 | 56 |
| 31 Dec 16 | 0 | -12 | 2 | 10 |
| 30 Sep 16 | 0 | -10 | 2 | 9 |
| 30 Jun 16 | 0 | -9 | 2 | 8 |
| 31 Mar 16 | 0 | -8 | 1 | 6 |
| 31 Dec 15 | 0 | -8 | 1 | 6 |
Kaliteli Kazançlar: BYSI is currently unprofitable.
Büyüyen Kar Marjı: BYSI is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: BYSI is unprofitable, but has reduced losses over the past 5 years at a rate of 15.4% per year.
Büyüme Hızlandırma: Unable to compare BYSI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: BYSI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Özkaynak Getirisi
Yüksek ROE: BYSI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.